Catalyst Pharmaceuticals (CPRX) Net Margin (2018 - 2026)
Catalyst Pharmaceuticals posted quarterly Net Margin of 42.66% for Q1 2026, up 254.0% year-on-year from 12.05% in Q1 2025, and up 41.75% on a QoQ basis from 30.1% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 9 years of Net Margin data on file, last reported at 42.66% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 254.0% year-over-year to 42.66%; the trailing twelve-month figure through Mar 2026 stood at 35.94% (up 80.0% YoY), and the FY2025 full-year result was 35.24%, up 383.0% from the prior year.
- Net Margin for Q1 2026 stood at 42.66%, up from 30.1% in the prior quarter.
- Across five years, Net Margin topped out at 56.38% in Q4 2022 and bottomed at 29.96% in Q3 2023.
- The 5-year median for Net Margin is 34.64% (2023), against an average of 31.37%.
- The widest annual swing landed in 2023, when Net Margin sank 6970 bps; it then surged 6406 bps in 2024.
- A 5-year view of Net Margin shows it stood at 56.38% in 2022, then tumbled by 73 bps to 15.41% in 2023, then jumped by 113 bps to 32.78% in 2024, then slipped by 8 bps to 30.1% in 2025, then soared by 42 bps to 42.66% in 2026.
- The last three Net Margin figures came in at 42.66% (Q1 2026), 30.1% (Q4 2025), and 35.57% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.65% |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 42.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.66% |
| Dec 31, 2025 | 30.10% |
| Sep 30, 2025 | 35.57% |
| Jun 30, 2025 | 35.55% |
| Mar 31, 2025 | 40.12% |
| Dec 31, 2024 | 32.78% |
| Sep 30, 2024 | 34.10% |
| Jun 30, 2024 | 33.24% |
| Mar 31, 2024 | 23.63% |
| Dec 31, 2023 | 15.41% |
| Sep 30, 2023 | -29.96% |
| Jun 30, 2023 | 37.92% |
| Mar 31, 2023 | 34.64% |
| Dec 31, 2022 | 56.38% |
| Sep 30, 2022 | 39.74% |
| Jun 30, 2022 | 40.70% |
| Mar 31, 2022 | 30.73% |
| Dec 31, 2021 | 24.30% |
| Sep 30, 2021 | 28.73% |
| Jun 30, 2021 | 33.50% |
| Mar 31, 2021 | 25.37% |
| Dec 31, 2020 | 36.88% |
| Sep 30, 2020 | 147.83% |
| Jun 30, 2020 | 33.03% |
| Mar 31, 2020 | 35.78% |
| Dec 31, 2019 | 26.32% |
| Sep 30, 2019 | 44.11% |
| Jun 30, 2019 | 38.01% |
| Mar 31, 2019 | -5.18% |
| Dec 31, 2018 | -2,899.92% |